# **A360 AI Global Library Data Sources for Aesthetic Medicine and Plastic Surgery**

As a data scientist supporting A360’s AI and *Global Library* initiatives, this report provides a comprehensive overview of data sources to **train, fine-tune, and enhance AI models** in aesthetic medicine and plastic surgery. We categorize sources into **Open Use Data** and **Restricted/Proprietary Data**, detailing for each: what the data is, where it’s hosted, licensing/usage permissions, ingestion methods, and how to transform it into structured entries. We then outline architectural patterns for a Dagster-managed ingestion pipeline, including source prioritization (accessibility, licensing clarity, clinical relevance, format). Finally, a summary table presents key details for each source (license, ingestion method, format, downstream use).

*(All citations are preserved in the format 【source†lines】 for reference.)*

## **Open Use Data Sources**

Open use data sources are publicly accessible and **legally usable for AI training and knowledge retrieval** (often under public domain or Creative Commons licenses). These include biomedical literature databases, government and professional datasets, open-access journals, regulatory data, and Creative Commons educational content. A360 can leverage these with minimal legal restrictions, using automated pipelines to gather and integrate knowledge into the Global Library.

### **PubMed and Open Literature (PubMed Central)**

**What & Where:** **PubMed** is a massive database of biomedical literature (hosted by NCBI/NIH) indexing 35+ million citations and abstracts of journal articles (including those on plastic surgery and aesthetic medicine). **PubMed Central (PMC)** is a repository of full-text articles, especially those that are open-access. Relevant content includes research on surgical techniques, case reports, clinical trials, and review articles in aesthetics and reconstructive surgery. PubMed’s web interface and **E-Utilities API** allow querying by keywords (e.g., “cosmetic surgery complications”) to retrieve article metadata and abstracts. Many full-text papers in this domain are available via PMC or publisher sites (especially if open access).

**Licensing/Usage:** PubMed abstracts themselves are typically copyrighted by journal publishers, but **PubMed Central’s Open Access subset** provides millions of articles under licenses that explicitly allow reuse. According to NIH’s data catalog, *“articles in the PMC Open Access Subset are made available for download under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work”*. This means A360 can safely use those articles for text mining, model training, or embedding with proper attribution. Many open-access journals deposit their articles in PMC under **CC-BY or CC-BY-NC** licenses (allowing reuse with attribution, sometimes restricting commercial use). Non-open-access articles (indexed in PubMed but not freely available) have “all rights reserved” – for those, A360 should refrain from ingesting full text without permission. However, *abstracts and metadata* are publicly queryable, and brief quotations or factual data from them can fall under fair use for scholarly purposes.

**Ingestion Method:** A360 can integrate PubMed/PMC data via:

* **NCBI E-utilities API**: to fetch article metadata and abstracts in XML/JSON. For example, a scheduled Dagster job can query new articles daily using keywords or specific journal feeds.

* **PMC OAI-PMH service or bulk FTP**: to download the Open Access subset in XML format. This provides full text of articles that can be parsed.

* **Web scraping**: For journals not in PMC but open on their site, a scraper can retrieve HTML or PDF content.  
   Once fetched, the pipeline should **parse and normalize** the content: for XML/HTML, extract title, authors, abstract, sections of interest (introduction, conclusions); for PDFs, use a PDF text extraction library. Metadata (journal, date, DOI) and the cleaned text can be stored as a **structured entry** in the Global Library. Each entry should retain a reference (URL or DOI) to enable citation and avoid ambiguity.

**Transformation & Use:** Abstracts and article sections can be used to fine-tune language models (since they contain domain-specific terminology and writing style). Full-text open articles can be chunked and embedded for semantic search (allowing the AI to retrieve relevant passages when answering questions). In the Global Library, these sources contribute evidence-based knowledge. Since licensing is permissive, the AI can even quote or summarize their content directly, as long as citations are provided. For non-open articles, the pipeline can store only metadata and maybe the abstract – the AI should then rely on summaries or avoid outputting non-public text. Overall, PubMed and PMC are **high-priority sources** due to high relevance and ease of automated access (robust APIs) with clear usage permissions for open subsets.

### **Open-Access Journals and Publications**

**What & Where:** In aesthetic medicine and plastic surgery, several **peer-reviewed journals are Open Access**, meaning their full content is freely available. Examples include *Plastic and Reconstructive Surgery – Global Open (PRS Global Open)*, *JPRAS Open* (the open-access version of Journal of Plastic, Reconstructive & Aesthetic Surgery), *Aesthetic Surgery Journal (ASJ) Open Forum*, and *Facial Plastic Surgery & Aesthetic Medicine* (some articles may be open access). These journals publish studies, case series, technical techniques, and reviews specifically in cosmetic and reconstructive surgery. Most are hosted on publisher platforms (e.g., LWW for PRS Global Open, Elsevier for JPRAS Open via ScienceDirect, etc.) and indexed in databases like PubMed and the **Directory of Open Access Journals (DOAJ)**.

**Licensing/Usage:** Open-access journals typically allow reuse under Creative Commons licenses. For instance, JPRAS Open offers articles under **CC BY or CC BY-NC-ND licenses** – authors choose whether others can use commercially or create derivatives. PRS Global Open, as an official open journal of ASPS, states that its content is *freely accessible to anyone* worldwide (and likely uses a CC BY-NC license via the publisher). Because of these licenses, A360 can **scrape or download** content from these journals, and incorporate it into the Global Library, provided that when content is exposed to end-users or included in outputs, appropriate attribution is given. The liberal licenses mean even direct quotes or full sections can be used for education or model training, as long as it’s not for profit (if NC clause applies) and no alterations if ND (no-derivatives) – though using it in a database or ML model typically counts as a transformation rather than redistribution.

**Ingestion Method:** A360 can obtain open-access journal content by:

* **Publisher APIs or feeds**: Some publishers provide RSS feeds for new articles or APIs for content. Elsevier’s APIs (if available for JPRAS Open) or OAI-PMH can be used to fetch article XML. Many open journals also deposit content in **PubMed Central**, which can be downloaded from there if available.

* **Scraping HTML**: If no API, use a crawler to visit each new issue’s table of contents, follow article links, and extract sections. The HTML structure often contains identifiable tags for title, abstract, references, etc.

* **PDF download**: Alternatively, download article PDFs (often offered on the site) and run PDF text extraction. This may be needed for figures or special formatting, but text extraction accuracy should be verified.  
   The ingestion pipeline should convert each article into a **structured format**: for example, store metadata (title, journal, year, author), abstract text, and possibly full body text or a summary of it. Linking the source URL or DOI is critical for future reference. Dagster can schedule this ingestion monthly or as new issues are released (some open journals publish continuously online).

**Transformation & Use:** Content from these journals provides **high-quality, peer-reviewed knowledge** for the AI. The data can fine-tune models on *clinical narrative style*, improve Q\&A systems by providing authoritative sources, and feed retrieval-augmented generation (the model can cite these articles to support answers). For example, if the AI is asked about outcomes of a specific technique, it could retrieve results from an open-access study and present them with citation. Because licensing is clear, the AI can quote key findings or guidelines from these articles directly. These sources rank high in relevance and **licensing clarity** (clear open licenses), though ingestion might require parsing complex documents. They should be prioritized after PubMed/PMC since many will overlap, but special effort is warranted to capture articles specific to aesthetic procedures that might not appear elsewhere.

### **FDA Databases and Regulatory Data**

**What & Where:** The U.S. Food and Drug Administration (FDA) provides several **open databases** relevant to aesthetic medicine, covering medical devices, drugs, adverse events, and approvals. Notably, **openFDA** is an initiative offering an easy API to access FDA datasets. Key data sources include:

* **Medical Device Reports (MDRs)**: adverse event reports for devices (e.g., implant failures, laser device injuries) from the **MAUDE** database.

* **Drug Adverse Events (FAERS)**: e.g., complications from dermal fillers or botulinum toxin (if categorized under drugs).

* **Device Registration and Listing**: information on manufacturers and devices, including those used in cosmetic procedures.

* **FDA Approvals and Safety Communications**: e.g., summaries of safety and effectiveness for approved aesthetic devices (implants, injectables), recall notices, or safety guidelines.

* **Drug Labeling (DailyMed)**: FDA-approved package inserts for drugs (like Botox, lidocaine, etc.) via NIH’s DailyMed API, giving detailed usage instructions and contraindications.

These datasets are hosted on FDA servers (open.fda.gov) and other government sites (nih.gov for DailyMed). They are machine-readable (JSON via API, or downloadable CSV/XML for some).

**Licensing/Usage:** Data provided by FDA is in the **public domain (CC0)** by default. The openFDA terms explicitly state: *“Unless otherwise noted, the content, data, documentation, code, and related materials on openFDA is public domain and made available with a Creative Commons CC0 1.0 dedication… You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.”*. This means A360 can freely use and redistribute FDA data. There are no copyright restrictions on factual data like adverse event statistics or device listings (and in fact, U.S. government data is broadly public domain). However, the **service** has usage policies (rate limits, etc.), and any *non-FDA-sourced content* (if present) would be identified separately. In summary, FDA data is very safe legally and can be fully integrated into the Global Library and AI models.

**Ingestion Method:** The **openFDA API** should be utilized for efficiency:

* Use REST API endpoints for relevant datasets (e.g., `/device/event`, `/device/510k`, `/drug/event`, `/device/registration`, etc.). Queries can filter data, e.g., retrieving all adverse events for a certain device type or all cosmetic use drugs. The API returns JSON which can be directly ingested.

* If large scale, openFDA also offers bulk download of datasets (in JSON or CSV). Dagster could orchestrate a one-time bulk import (for historical data) and then periodic API calls for updates (as new reports come in, which is typically daily or weekly).

* Other FDA data: For drug labels, DailyMed has an API that returns XML for each label; for FDA approvals, the FDA website might require scraping of press releases or use their datasets on device approvals.

* **Parsing & Storage:** Ingested JSON can be transformed into structured records. For example, each adverse event report has fields like event type, date, device name, narrative. The pipeline can normalize terminology (e.g., map device identifiers to common names) and store key fields relevant to clinicians (like complication rates). For device listings or approvals, the data can be stored as reference entries (e.g., “Device X – approved indications, manufacturer, approval date”). All data should be time-stamped and source-referenced (e.g., include the FDA record ID or link).

**Transformation & Use:** FDA data provides **real-world evidence and reference info**. Downstream, A360’s AI can use these data in multiple ways:

* **Knowledge Base Queries:** The Global Library can answer questions like “What complications have been reported for Device X?” by querying the ingested MDR data. Because it’s structured, the AI (or a retrieval system) can aggregate counts or pull specific cases, supplementing its answers with data.

* **Training AI models:** The textual portions (like event narratives or drug label sections) can fine-tune models to better understand medical device safety language or regulatory phrasing. More importantly, structured data (numbers, classifications) won’t directly train a language model but can be embedded or indexed for tools like decision support (e.g., a complication rate can be inserted into a generated care plan).

* **Clinical Decision Support:** Knowledge of FDA approvals means the AI can check if a suggested treatment is FDA-approved and for what indications. Adverse event data can inform risk discussions in care plans. Since licensing is not an issue, the AI can freely incorporate these facts and even quote FDA public documents. The pipeline should **prioritize FDA data early**: it’s accessible (robust API, as noted) and very relevant to patient safety and compliance, which are crucial in aesthetic practice.

### **Clinical Trials and NIH Open Data**

**What & Where:** **ClinicalTrials.gov** is a registry of clinical studies, including many trials on cosmetic treatments, new devices, or surgical techniques. It’s maintained by NIH/NLM, listing study protocols and results for thousands of trials worldwide. For example, trials for novel dermal fillers, stem-cell treatments for skin rejuvenation, or comparisons of surgical methods are registered here. Each trial record includes structured fields: study title, status, interventions, outcome measures, and sometimes summary results. In addition, NIH and other governmental bodies host open datasets relevant to medicine (though not cosmetic-specific, some general resources could be useful, like anatomical databases or imaging datasets if we ventured into AI vision – not our main focus here).

**Licensing/Usage:** Information on ClinicalTrials.gov is intended for public use. The site is a U.S. government publication, and submitters know the data will be publicly available. While individual study descriptions are authored by trial investigators (thus technically copyrighted by them), the act of submission to a government registry likely grants an implicit license for public dissemination. In practice, **trial records are treated as public domain** data for use in analysis and summaries. (No explicit license is stated, but the *purpose* is public knowledge, and facts from trials are not protected.) Government-generated elements (like NLM indexing or result summaries created by federal employees) are definitely public domain. Therefore, A360 can ingest trial metadata and even brief descriptions freely. If reusing wording from detailed descriptions, it should be minimal and cited, but generally the data (names, numbers, outcomes) can be extracted as facts.

**Ingestion Method:** ClinicalTrials.gov provides multiple access methods:

* **REST API** and **bulk download**: There’s a JSON API for querying studies (by condition, keywords, etc.), as well as downloadable XML files for the entire registry or specific subsets. The pipeline can periodically pull all trials related to aesthetic keywords (e.g., “plastic surgery”, “cosmetic”, specific procedure names).

* **Filtering & parsing:** Once data is retrieved (in XML/JSON), the pipeline should filter to relevant trials (exclude irrelevant medical studies). Key fields like “Intervention Name”, “Condition”, “Outcome Measures”, and “Results (if posted)” should be parsed. The output can be a structured entry per trial: e.g., *“NCT123456: A randomized trial of Laser X for scar treatment – completed 2024, result: 30% improvement vs control”*.

* If results are posted, those are usually in tables (efficacy outcomes, adverse events rates) – the pipeline can tabulate those facts. Otherwise, the presence of a trial itself is valuable (to know ongoing research).

**Transformation & Use:** This data helps the AI provide **evidence-based answers and awareness of research**. For example:

* The AI could be asked about experimental treatments; knowing what trials are underway or completed allows it to respond with up-to-date information (“There is a clinical trial (NCTxxxx) investigating \[topic\], but results are not published yet.”).

* Aggregating results from multiple trials can inform best practices (like a meta-analysis). The pipeline could later integrate with a system that updates a summary of evidence (a meta-analysis extraction).

* Since trials data is structured, the AI can use it in a factual manner. E.g., “According to ClinicalTrials.gov, 5 trials in the last 5 years studied technique Y, showing improvement in outcome Z.” Facts from these records (like number of participants, outcome values) are not copyrighted and can be output directly. This is **high relevance** for clinical decision support (especially if no other literature yet exists for novel treatments).

* Dagster can schedule periodic updates (monthly or quarterly) since new trials appear frequently. Licensing is clear (public domain intent), and format (XML/JSON) is structured – making this a **medium priority** ingestion (very useful, though perhaps secondary to published literature in terms of direct clinical guidance).

### **Professional Society Guidelines and Statistics**

**What & Where:** **Professional societies** in plastic surgery and aesthetics publish valuable open content:

* **Clinical guidelines or consensus statements:** Occasionally, societies like the American Society of Plastic Surgeons (ASPS) or The Aesthetic Society publish guidelines (e.g., on patient safety, procedural checklists, credentialing) that may be openly accessible on their websites or in journals. These might be PDF reports or position statements.

* **Annual Statistics Reports:** ASPS releases a comprehensive *“Plastic Surgery Statistics Report”* each year, detailing the number of surgical and minimally-invasive procedures performed, demographic breakdowns, and trends. Similarly, the International Society of Aesthetic Plastic Surgery (ISAPS) publishes a *Global Survey* of cosmetic procedures worldwide every year. These reports (often PDF documents) are freely available on their websites for public and media use.

* **Educational resources:** Some societies provide open-access educational content for surgeons (for example, ASPS EdNet might have free modules, or ISAPS may have public videos and articles about techniques). Also, conference abstracts or presentations can be openly published (e.g., PRS Global Open has meeting abstracts in supplemental issues).

**Licensing/Usage:** Content from professional organizations is usually © by the organization, but they *intend public dissemination*. The annual statistic reports, for instance, are published for anyone to download; while marked “All Rights Reserved” in fine print, using the data within (the numbers and high-level findings) is generally allowed with credit. Factual data like “there were 300,000 rhinoplasties in 2024” is not protectable – A360 can freely use those statistics (with a citation to ASPS). If directly quoting narrative portions (like an introductory analysis or a guideline’s wording), that should be done sparingly and with attribution (likely fair use due to educational context). Many guidelines, if authored by doctors and published in journals, might be open access; if not, we treat them like other restricted literature (summarize instead of copy). Overall, **data and factual findings \= free to use**, whereas full-text narrative \= check license (but often these PDFs are openly accessible and can be referenced).

**Ingestion Method:**

* **Web scraping/downloading:** The pipeline can retrieve these from the societies’ websites. For example, ASPS posts PDFs for each year’s statistics; the pipeline can download the latest PDF each year (or whenever updated) and parse it (potentially using PDF-to-text or extracting tables if needed). ISAPS likewise has a page listing survey reports by year – these can be scraped or manually added since they update annually.

* **Parsing:** These documents contain structured data (tables, charts) and some commentary. The ingestion process should focus on capturing the **structured data**: number of procedures by type, trends over years, etc. It may convert PDF tables into a CSV or database entries (like “2024 – 350,000 Botox injections” etc.). If the PDF text is parseable, key statements (e.g., “Overall procedures increased 5% from last year”) can be extracted as well.

* **Guidelines/Statements:** If there are text-heavy guideline documents, the pipeline can store them as text segments. However, because they might be copyrighted, a safer approach is to **summarize** them. A human-in-the-loop could review a guideline and input a distilled summary of key points into the library. Alternatively, if the guideline is open access via a journal, ingest it fully as per the journal’s license.

**Transformation & Use:** These sources are **directly relevant to clinical decision-making**:

* The statistics inform **trends and context** (helpful for AI-generated reports or to answer questions like “What’s the most common cosmetic surgery?” or forecasting needs). The AI can use these numbers in answers or planning tools (e.g., “We see increasing demand for X procedure, which might influence training focus.”).

* Guidelines provide **practical recommendations** (e.g., how to handle a certain complication or candidate selection criteria). The AI should incorporate these into its knowledge base to enhance clinical decision support. For instance, if a guideline says “Patients on medication Y should discontinue 2 weeks before surgery,” the AI’s care plan generator can include that advice.

* Because these are from authoritative bodies, the AI can **cite them as high-quality sources** to build trust. The pipeline should mark these entries as high-priority references.

* The Dagster pipeline might treat these as special cases: not high volume, but high importance. It could run a periodic check for new or updated content (yearly for stats, or quarterly for any new guidelines/news releases). Since scraping a PDF is needed, it’s slightly manual, but the low frequency is manageable.

* In prioritization, these rank high on *relevance* and *format compatibility* (often PDF/text). Licensing is a slight gray area, but given the public-facing nature, using this data internally and in summarized outputs is low-risk (and often explicitly encouraged by the source when credited).

### **Medical Device Manuals and Technical Documents**

**What & Where:** **Device manuals** and technical datasheets for equipment (lasers, ultrasound devices, cryolipolysis machines, etc.) and products (e.g., breast implant IFUs – Instructions for Use) are rich sources of practical information: operating parameters, contraindications, maintenance, and safety precautions. Many manufacturers host PDFs of user manuals or physician guides on their websites (for example, a laser manufacturer might have a “Resources” section). Regulatory filings can also include technical documents: for instance, the FDA’s database of device approvals often contains a Summary of Safety and Effectiveness (for PMA devices) or 510(k) summaries, which describe the device and its tested outcomes.

**Licensing/Usage:** **Caution:** These documents are typically copyrighted by the manufacturers or authors. They are openly accessible (no paywall), but not “open license.” This places them in a gray zone between open and restricted. However, A360 can still utilize them under *fair use and transformation* principles:

* **Facts and data in manuals** (e.g., laser wavelength, recommended fluence ranges, or step-by-step procedure) are not protectable.

* **Direct text** (explanations, instructions) is copyrighted – the AI should not regurgitate large verbatim chunks. Instead, it can **summarize** or **extract key points**. For example, extracting a table of device settings or paraphrasing a safety warning (“The manual for Device X warns to avoid use on patients with pacemakers”) is likely fair use, especially for educational/internal use.

* When integrating into the Global Library, it’s best to store either the *transformed data* (like a structured list of device specs) or very brief quotes rather than entire manuals. If needed, flag these entries as “restricted content” so that any AI output referencing them is carefully controlled (e.g., only output a sentence or two with attribution to the manual).

* Legally, using manuals internally for model training is probably fine (since the model learns the underlying patterns, similar to how a human would learn from the manual). The risk is if the model were to output the manual text. To prevent that, the strategy is to use these documents to **feed facts into knowledge base entries or embedding vectors** that link back to the manual. The AI can then use the knowledge without exposing the full text.

**Ingestion Method:**

* **Scraping/Downloading:** Identify key devices of interest (perhaps those commonly used by A360 or partners) and find their manuals. This could be done via web search or a curated list. Some manufacturer sites allow direct download (PDF), others might require a form (which could be bypassed or done manually if needed). FDA’s site can be used for certain documents: the 510(k) or PMA summaries are available in HTML/PDF and contain technical info.

* **Parsing:** Manuals are PDF-heavy and may include images, charts, etc. Automated text extraction can get the text content. The pipeline might focus on sections like “Indications”, “Contraindications”, “Usage Guidelines”, “Maintenance”, and “Warnings”. Using keyword-based parsing or known section headings can help isolate those parts.

* **Transformation:** Instead of storing the full text, the pipeline can create a **structured summary**. For example: *Device: CoolSculpting; Type: Cryolipolysis; Indication: fat reduction; Key Warnings: not for patients with cryoglobulinemia; Common Settings: temperature X for Y minutes.* This could be represented in JSON or a table format in the library. If certain phrasing is crucial (like a specific warning), include a one-line quote in quotation marks with the manual citation.

* Some data (like technical specs) can be directly stored as facts (these are not expressive text but numbers or lists). This effectively transforms the manual into a database entry that’s easy for AI to reference without containing large copyrighted text blocks.

**Transformation & Use:** Device manuals contribute to **operational and safety knowledge**:

* The AI can use this information when generating **protocols or answering operational queries**. For instance, if asked “What are the contraindications for laser treatment X?”, the AI (having ingested the manual summary) can list those contraindications accurately, citing the device manual or approval info.

* For **embedding and retrieval**: Even if we don’t expose manual text, having manual content embedded means the AI can recognize when a query matches something that was in a manual and then respond with the paraphrased answer. This is a “citation-driven embedding” approach – the content is indexed, and if used, the AI can point the user to the manual for more details rather than giving them the raw text.

* In the Dagster pipeline, adding device manuals might be a **secondary priority** (since it’s a bit more labor-intensive and legally sensitive than open data). It could be a *curated ingestion*, where periodically the team adds new device documents as needed (especially if A360 is expanding into using that device). The volume is not huge per year (devices are finite), so a semi-automatic plus human curation approach works.

* Licensing clarity is low (not clearly open), so usage must remain **transformative** (summaries, facts). Given their relevance to practice, they are worth including, but with compliance measures (e.g., internal review of the extracted content to ensure no large verbatim sections).

### **Creative Commons Educational Content (Wikis, Images, OER)**

**What & Where:** A variety of **Creative Commons-licensed medical content** can enrich the Global Library:

* **Wikipedia and Medical Wikis:** Wikipedia has detailed articles on many plastic surgery procedures (e.g., “Rhinoplasty”, “Liposuction”) and related anatomy or pathology (injection techniques, wound healing). All Wikipedia text is licensed CC BY-SA 3.0, meaning it can be shared and adapted with attribution. There are also specialty wikis (like WikEM for emergency medicine, Radiopaedia for radiology images, etc.) which use CC licenses (often CC BY-NC-SA). While not all aesthetic-specific, entries on wound care or anatomy can be relevant.

* **Open Educational Resources (OER):** These include open-access textbooks or modules. For example, the *Open Access Atlas of Otolaryngology and Head & Neck Surgery* includes chapters on facial plastic procedures (under a Creative Commons license). Some university lecture notes or online courses in plastic surgery might be shared under Creative Commons. Additionally, resources like **MedlinePlus** (patient-facing info from NIH) have some content in public domain or under permissive terms for reuse (though one must check each item).

* **Images and Media:** Platforms like **Wikimedia Commons** host images of surgical anatomy, condition examples, etc., under licenses like CC BY or CC BY-SA. There might be image sets (e.g., before-and-after photos released with permission, or anatomy diagrams) usable for model training (if A360 ventures into computer vision or just for illustration in the Library). Also, some YouTube videos are explicitly released under Creative Commons licenses (YouTube allows creators to mark videos as CC BY) – those could be used more liberally if any are relevant.

**Licensing/Usage:** All these are explicitly open licensed:

* **Wikipedia:** CC BY-SA means A360 can copy, modify, and use the text as long as it credits Wikipedia and if sharing the content onward, does so under the same license. For internal use or AI training, that’s no issue; if any content is presented to users, just note the source (e.g., “(Source: Wikipedia)” in a citation).

* **Other CC content:** License details vary (BY, BY-SA, BY-NC, etc.), but fundamentally they allow reuse. If non-commercial (BY-NC), A360 must ensure content use remains in a non-commercial context (if A360’s Global Library is part of a paid service, caution: NC content might be problematic, so prefer BY or public domain sources for integration into a commercial AI).

* **Public domain resources:** Some U.S. government educational content (CDC infographics, NIH factsheets) are public domain and can be freely incorporated.

* Attribution is the main requirement for CC content. The pipeline should store the necessary attribution metadata (e.g., original URL, author if provided) to include when the AI outputs that information.

**Ingestion Method:**

* **Web scraping/API:** Wikipedia can be accessed via its API to get page content in wikitext or HTML. A targeted approach is best: identify a set of relevant articles (perhaps use Wikipedia’s category system for “Plastic surgery” or “Cosmetic medicine”) and retrieve them. The pipeline can refresh these periodically since wiki content updates.

* Clean the text (strip markup) and perhaps shorten it (Wikipedia can be verbose or contain sections not needed). For the Global Library, we might store a *summary or key sections* (like the overview and complication sections of a procedure article). Tools like *Wiki API \+ summarizer* can automate this, or use existing summaries from the article lead.

* **Other OER/Textbooks:** If there are PDFs or online texts under open license, treat them similar to journals – download and parse. Because they may be large, consider focusing on chapters of interest (e.g., a chapter on breast reconstruction from an open textbook).

* **Images:** Download image files along with their captions and license info. These can be stored in an image library for reference. (For AI model training, images could be used to train a vision model to identify surgical landmarks, but that’s beyond textual ingestion scope.)

* Dagster can coordinate a periodic *crawl of known CC sources*. The volume of this content isn’t huge and doesn’t change as rapidly as journals. Perhaps a quarterly refresh of Wikipedia articles, and manual addition of any new OER found.

**Transformation & Use:**

* **Augmenting Knowledge:** CC text can fill gaps in the AI’s knowledge with general explanations. For instance, Wikipedia often covers background (history of a procedure, basic descriptions) which complements the technical focus of journal articles. The AI can use this to better explain concepts to users or when generating patient-friendly content.

* **Patient Education:** Wikipedia/MedlinePlus content, being layperson-accessible, is valuable if A360’s tools generate patient handouts or aftercare instructions. The AI can draw from these sections to ensure information is understandable. Since it’s open license, quoting or closely paraphrasing is fine (still cite the source to maintain trust).

* **Image utilization:** If the Global Library has an interface, having images of anatomy or results with CC licenses can enhance the content. For AI tasks like image analysis (if any), these could be training data (though ensure appropriate use if any face/patient images – many might be illustrative diagrams which are safer).

* From an **architectural standpoint**, CC content is **low-hanging fruit** – easy to obtain, no legal barriers, but one must ensure quality (community-maintained content like Wikipedia may have errors). Thus, it’s useful for general knowledge and definitions, but for critical clinical guidance, it should be supplemented with peer-reviewed sources. Prioritize it for breadth and patient-level info, but not as primary source for controversial topics without verification.

## **Restricted or Proprietary Data Sources**

Restricted or proprietary sources are those **not openly licensed for reuse** – typically copyrighted content such as commercial publications, media (videos/podcasts), or private data. Directly ingesting or training on these carries legal risk. However, these sources often contain valuable insights. A360 can pursue **legally compliant strategies** to leverage them: using human-in-the-loop summaries, extracting only non-copyrightable data points, creating embeddings for internal search, or performing meta-analyses. The guiding principle is to **transform the content** so that the AI’s use is either fair use or does not disclose the protected material verbatim. Below, we outline key proprietary source types and how to handle them:

### **YouTube Videos (Procedural & Educational Content)**

**What & Where:** **YouTube** hosts a wealth of videos on plastic surgery and cosmetic dermatology. These include:

* Surgical procedure recordings (often uploaded by surgeons or clinics, demonstrating techniques like rhinoplasty, facelift, etc.).

* Educational lectures and webinars (e.g., conference recordings, surgeon’s YouTube channels explaining concepts).

* Patient testimonials or Q\&As.  
   For A360’s purposes, the first two categories are most relevant for clinical knowledge. These videos can offer practical pearls, technique demonstrations, and commentary that may not be captured in text literature.

**Licensing/Usage:** By default, YouTube videos are under **standard YouTube license** (all rights reserved by the creator). Downloading or reproducing them is against YouTube’s terms of service except via YouTube’s API for certain data. However, *using the information contained in them* can fall under fair use if done transformatively:

* **Transcription**: Converting speech to text is making a copy of the content – that text is still copyrighted. But if we use the transcript only internally for analysis, and especially if we **summarize or extract facts**, we can argue transformation.

* **Summarization**: A summary of a video in original words is a new copyrighted work (by A360) and does not infringe the original (especially if it doesn’t include extended verbatim quotes). This is a **human-in-the-loop summarization** approach: have an AI or human draft a summary of the key educational points from the video, which can then be used freely.

* **Small snippets**: Under fair use, using short quotes or clips for commentary is allowed (e.g., quoting a single sentence a surgeon said, within a larger context, might be fine).

* **Attribution**: Even though not legally required by fair use, it’s good practice (and for end-user value) to cite the video (with a link) if its content influenced the AI’s answer.

Therefore, A360 **should not ingest entire video transcripts verbatim into the library** accessible to the model for output. Instead, focus on *derived data*: summaries, key points, timestamps of important moments (if linking back), etc. The original video remains the primary source users can be pointed to for full details.

**Ingestion Method:**

* **YouTube API**: Use the YouTube Data API to search for relevant videos or to retrieve metadata for known channels. The API can provide video titles, descriptions, and captions (if the uploader provided subtitles or if auto-caption is enabled and accessible via API in some cases).

* **Transcription**: If high-quality captions are not available via API, the pipeline can download the audio (YouTube’s terms forbid downloading video except via their API, but one can legally use the **YouTube Captions** if available, or use an automated speech recognition on the audio stream which is arguably a created work by A360). A360 might apply a speech-to-text model (like Whisper) on videos to get transcripts.

* **Processing**: Once text is obtained, the pipeline should generate a **summary or outline**. This could be AI-assisted: e.g., use a summarization model to draft a summary, then have a human reviewer (subject matter expert) verify accuracy and compliance (this is the “human-in-the-loop” verification for high-stakes content). Alternatively, the pipeline could flag segments that match certain keywords and store those as Q\&A pairs (e.g., a video Q\&A: “How long is recovery from facelift?” – store that answer in text with attribution).

* **Storage**: Save only the processed summary or discrete facts. For instance: *Video “Dr. X’s Rhinoplasty Tutorial” (YouTube) – Summary: covers prep, marking, step-by-step technique; Key tip: preserving dorsal hump to avoid open roof deformity.* Include the video URL and maybe timestamped pointers for reference. The raw transcript can be kept in a restricted datastore (for internal search purposes), but not directly used in generation.

**Transformation & Use:**

* Summaries of videos can be treated like mini-articles in the Global Library. The AI can retrieve knowledge from them when needed (e.g., if asked about a surgical technique nuance, a tip mentioned in a video summary could be provided).

* **TF-IDF/Keyword Indexing:** Another approach is to index the transcript text (or summary text) to allow search. A TF-IDF or vector index of the transcripts lets the AI find relevant parts without storing or exposing the full text. This is similar to how Google Books search was ruled fair use – the system indexes the full text but only shows *snippets*. A360’s AI could do the same: if a user query is answered by video-derived knowledge, provide a snippet or a paraphrase and then **cite the video link**. This way, the user is directed to the original content for full context, satisfying fair use by not supplanting the original.

* **Embedding with citation:** We can embed the knowledge in vector form so the model “knows” about it, but when that knowledge is surfaced, design the AI to output it as *“According to \[Dr. X’s video on YouTube\], one key step is ...”* rather than giving a large chunk of the video transcript. This ensures the original creator gets credit/traffic and reduces legal risk.

* **Priority and Feasibility:** YouTube content is highly relevant (especially for practical how-to knowledge), but the ingestion is **complex** (requires ASR and summarization). Also, content quality varies; we’d likely select known reputable creators or society channels. This might be a **phase 2** in pipeline after gathering easily-gettable text sources. Once set up, periodic checks (maybe monthly) for new videos from selected channels or on specific topics can keep the library updated.

### **Medical Podcasts and Webinars**

**What & Where:** The last few years have seen growth in **podcasts** and recorded webinars focusing on plastic surgery and aesthetic medicine. Examples include interview-format podcasts with experienced surgeons, discussions of new research (journal clubs), or audio from conferences. A360 may have transcripts (as indicated by the provided `podcast_transcriptions.csv`) of some podcasts. These audio sources contain insights, opinions, and knowledge sharing in a conversational format, which can complement formal literature.

**Licensing/Usage:** Podcasts are usually copyrighted by their creators (often implicitly via the platform’s terms). They are publicly accessible (free to listen), but not in the public domain. Using them requires the same care as YouTube:

* **Transcribe and summarize, don’t reuse full text.** An hour-long podcast transcript is essentially a written article’s worth of text – directly using that is infringement. But summarizing each episode or extracting specific facts (with attribution to “Podcast X episode on \[topic\]”) is transformative.

* **Human-in-loop curation** is valuable: audio can have transcription errors, and not all content is high value. Having a human decide what pieces of a podcast are worth integrating (or even directly writing a summary) can maximize utility and minimize noise.

* **Permission:** In some cases, A360 could reach out to the podcast creators for permission to use transcripts in the library. If granted, that could open up more direct use. Otherwise, proceed under fair use assumptions (informational excerpts, commentary).

**Ingestion Method:**

* **Identify relevant podcasts:** e.g., *The Plastic Surgery Podcast*, *Beauty and the Biz*, *Behind the Knife (plastic surgery episodes)*, *PRS Global Open Keynotes* (the open journal’s own podcast), etc. Gather their RSS feeds (which list episodes).

* **Automated transcription:** For each new episode, download the audio via the podcast RSS (usually an mp3 link) and run ASR to get text. The `podcast_transcripttions.csv` suggests this might have been done already for some.

* **Summarization/Indexing:** Similar to videos – create a summary of the key points discussed. Structure it as an article or Q\&A if applicable (podcasts often have Q\&A format or narrative; we can break it into thematic chunks).

* **Store** the summary text and metadata (episode title, date, participants). If any specific quotes are noteworthy (e.g., a surgeon’s quote about their personal technique), include a short quote with the person’s name, as that can enrich the library (just ensure it’s a short snippet, which is okay under fair use especially if it’s factual or an opinion rather than creative expression).

* Optionally, index the full transcript for internal search (with a system to only output snippet \+ citation as needed).

**Transformation & Use:**

* **Expert Insights:** Podcasts often provide context and rationale behind decisions, which can help the AI give nuanced advice (like “Expert A emphasizes the importance of patient selection for procedure Y”). Having these perspectives in the library can make AI responses more well-rounded.

* **Current Trends and Unpublished Tips:** Some content in podcasts might not be found in literature (like off-label uses or emerging trends). Including these (with caution and labeled as such) can update the AI’s knowledge base beyond what’s in journals.

* **Usage in AI Outputs:** The AI should attribute any knowledge drawn from podcasts to maintain transparency (e.g., “In an interview on *\[Podcast Name\]*, Dr. Y noted that...”). This not only is good practice but also avoids presenting someone’s idea as the AI’s own. It effectively functions like citing an oral source.

* On the technical side, integrating podcasts is akin to integrating YouTube: a bit **resource-intensive** (transcription) and needing summarization. It should be somewhat prioritized because the content is highly relevant and fairly accessible (audio is easier to process than video in terms of file size). A schedule (e.g., weekly) to grab new episodes from selected podcasts can be implemented in Dagster. Ensuring transcripts are reviewed for accuracy (especially medical terms) is key – possibly incorporate a step to correct terminology.

### **Commercial Journals and Textbooks**

**What & Where:** This category includes **all content under traditional copyright with no free license**, such as:

* Subscription-based journals (e.g., *Plastic and Reconstructive Surgery* (the main journal), *Aesthetic Surgery Journal* (main), *Journal of Craniofacial Surgery*, etc., which are paywalled except maybe abstracts).

* Medical textbooks and reference books (e.g., “Neligan’s Plastic Surgery” volumes, “Grabb and Smith’s Plastic Surgery”, etc.).

* Commercial e-learning content or articles by companies (e.g., a device company’s training materials that are not publicly posted, or an online course that requires purchase).

These contain validated and comprehensive knowledge (textbooks compile years of expertise; journals have the latest studies). They are valuable but **cannot be freely copied or fed to AI** without violating copyright, unless A360 has a specific license or partnership to use them (which is outside our scope here).

**Licensing/Usage:** All rights are reserved by publishers. A360 must treat these carefully:

* **Do not ingest full text or figures from these sources into the Global Library** without permission. Even if internally accessible, the risk of the AI regurgitating passages is high if they were in training data.

* **Leverage through summaries and facts:** Use a *literature review approach*. For example, have medical writers or the AI (with human oversight) read an important article and **extract key data** (numbers, outcomes) and **summarize conclusions in original words**. This summary, coupled with a citation to the original, can be stored. The summary is a new work (so copyright A360) and includes only facts and analysis – this is fair use and also standard scholarly practice.

* **Meta-analysis extraction:** If multiple proprietary sources cover a topic, we can create a meta-summary that synthesizes all (e.g., “10 studies (refs) indicate that technique A has a 5% complication rate”). Such synthesis is highly transformative and not a copy of any single source, thus safe to use. Each fact in it should be traced to a citation (which the Global Library can store as references).

* **Data Tables:** Facts and data (numbers, statistics) from studies or textbooks are not protected by copyright. So, A360 could populate a database of factual knowledge (e.g., “Implant rupture rate \= X% according to \[Journal, 2022\]”) extracted from literature. This doesn’t infringe because it’s just facts with attribution.

**Ingestion Method:** Direct automation is hard due to paywalls. Strategies:

* **Library access and manual curation:** If A360’s team has access to these journals (through institutional subscriptions or individual purchase), they could download PDFs and have a text extraction. But using that text for anything other than manual reference is legally risky. Instead, one could use text mining tools behind the scenes to identify relevant sections (for instance, find where an article discusses a specific outcome), then have a human read and paraphrase.

* **Text mining APIs:** Some publishers (e.g., Elsevier, Springer) have text-mining APIs for subscribers or partnership programs. If available, one could programmatically get text with certain restrictions (like must obey publisher’s terms on how much text can be stored). This might be complex; likely easier is the manual approach above.

* **Citation indexing:** Build an index of references and abstracts from these sources (abstracts are usually publicly available via PubMed). The abstract can be stored (abstracts are short and arguably fair to keep; they often are in PubMed so presumably allowed to reuse in that context). The abstract plus a link might suffice for some knowledge needs. If more detail is needed, mark that source as one requiring human or further lookup.

* **Expert input:** Another approach is incorporate knowledge through expert-written content. For example, A360 could commission an “Aesthetic Surgery Knowledge Base” writing project where experts summarize textbook chapters in original language. Those summaries (owned by A360) populate the Global Library. This bypasses direct copyright issues and ensures quality (this is indeed human-in-the-loop creation at a large scale).

**Transformation & Use:**

* The transformed outputs (summaries, fact databases) drawn from proprietary sources can now be used by the AI similarly to open sources. The AI can answer with these synthesized insights and **cite the original source** (which is good academically and also avoids exposing too much of the source’s content – the user would need to read the cited source for full details, which is how fair use search engines and reviews operate).

* For instance, if asked “What’s the long-term failure rate of cartilage grafts in rhinoplasty?”, the AI might have a stored fact like “According to *Journal of XYZ 2023*, \~10% of cartilage grafts may resorb over 5 years【source】.” This gives the user useful info and points them to the journal, without the AI having stored the entire article text.

* **Embedding approach:** We could embed full text of these articles in a vector space to allow the model to reason on them without storing them in readable form. Since an embedding is a mathematical abstraction that cannot reconstruct the original text, this is often seen as acceptable use. The model could then answer questions drawing on that embedded knowledge, ideally phrasing in its own words. (We should still cite the source if we know which article the info came from, hence “citation-driven embedding” – we maintain mapping from vector to source). However, this is technically tricky (keeping track of which chunks correspond to which source in the vector store, but it’s doable with metadata in modern vector databases).

* **Prioritization:** These sources are **high-value but high-effort**. They should be considered once the open sources have been exhausted, or for very critical topics not well covered in open data. Legally, they are the most restrictive; thus, any ingestion pipeline dealing with them should be separate and possibly require a human approval step for each piece of content that enters the library (to ensure it’s sufficiently transformed). In a Dagster context, one might create a pipeline where articles are queued for “summary”, then a human reads and inputs summary, then it gets ingested – combining automation with manual work.

### **Internal or Proprietary Clinical Data *(if applicable)***

*(Note: The task description doesn’t explicitly mention using internal data like patient records, but for completeness, we address it briefly.)* If A360 has access to any proprietary datasets such as de-identified patient outcomes, clinical imaging, or device usage data from partners, those are also not open. Their use would require strict compliance (e.g., HIPAA for patient data, agreements for partner data). Typically, such data could be used to fine-tune models internally (with privacy safeguards) but would not be part of the public Global Library. Ingestion of these would follow a secure pipeline path (not mixed with public data), and usage likely for model training or analytic insights rather than direct query by end-users. Licensing here is governed by data-sharing agreements rather than public licenses. Any outputs derived (like a model that predicts outcomes based on this data) must not reveal individual data. We mention this only to note that if such data exists, it’s handled separately from the “Global Library” content.

## **Data Ingestion Architecture (Dagster Pipeline Patterns)**

To manage the diverse sources above, we propose a **Dagster-managed ETL pipeline** system with modular assets for each source. Dagster will orchestrate extraction (from APIs, web, files), transformations (parsing, cleaning, summarizing), and loading into the Global Library database or knowledge store. Key architectural considerations and patterns:

* **Modular Pipelines per Source:** Each data source (or group of similar sources) will have its own pipeline or Dagster job. For example, a PubMed pipeline, an openFDA pipeline, a YouTube pipeline, etc. This separation allows tailored logic for each format and independent scheduling. Dagster’s asset grouping can reflect this (e.g., one software-defined asset for “PubMed latest articles dataset”).

* **Batch Ingestion & Incremental Updates:** Initial seeding from historical data (e.g., load all existing open access journal articles, all FDA data to date) and then incremental updates. Use unique IDs (PMIDs, NCT IDs, etc.) to avoid duplication. Dagster schedules (or sensors) can check for new data: e.g., a daily run that queries PubMed for any new entries since last ID or date.

* **Parallel Processing:** Many sources can be processed in parallel without dependency. Dagster can launch multiple workers for different sources simultaneously (respecting API rate limits). Within a source, if we break data into chunks (e.g., 100 articles per API call), those can also parallelize to speed up ingestion.

* **Unified Data Schema:** Define a **common schema** for the Global Library entries, to the extent possible. This might include fields like `source_type` (journal article, guideline, video, etc.), `title`, `author_or_creator`, `date`, `content_text` (could be full text, summary, or structured data in JSON), `license`, and `source_url/citation`. Each pipeline maps raw input into this schema. Additional fields for certain types (like `study_design` for trials, or `statistics_data` for reports) can be attached as needed (Dagster’s asset metadata or storing JSON fields).

* **Storage and Indexing:** The pipeline will load processed data into:

  * A document database or search index for unstructured text (for supporting semantic search and retrieval-augmented generation).

  * A relational database for structured fields and metadata (to support filtering, analytics, or building the “library” UI).

  * A vector store for embeddings if using vector search (embedding could be done in a later stage once text is in the library).  
     Dagster can trigger an embedding step after new text entries are added (using an ML model to encode text to vector and store in a vector DB).

* **Quality Control & Observability:** For sources like AI-generated summaries or OCR’d text from PDFs, integrate a review step. Dagster can pause or flag assets for review if certain conditions are met (e.g., low confidence in OCR, or AI summary length deviates). We can maintain logs or data validation checks (for example, ensure each entry from openFDA has required fields; ensure no entry exceeds a length threshold which might indicate unprocessed text).

* **Error Handling and Retry:** Web sources might fail (network issues or changes in HTML). Dagster should catch exceptions and either retry or alert. Implement timeouts and backups (if API fails, skip until next run to avoid blocking others). Keep track of last successful ingest points so a failed run can continue later.

* **Source Prioritization Mechanism:** Some sources are more critical (e.g., FDA, PubMed) and should be ingested first or more frequently. Dagster can prioritize via scheduling frequency (e.g., PubMed pipeline runs daily, YouTube weekly). If resource constraints occur, critical pipelines can have more resources allocated.

* **Scalability:** Design for new sources to be added easily. Use config files or metadata to define a new source’s parameters (URL, type, parsing rules) so that adding, say, a new open-access journal is a matter of configuration rather than writing entirely new code. Dagster’s configurability can allow pipelines to be instantiated per journal if needed using the same code with different inputs.

* **Compliance and Separation:** Maintain a clear separation in processing and storage between open and restricted content. For example, restricted content summaries might be tagged and stored in a way that the AI knows not to output them verbatim. If necessary, maintain two vector indexes – one for fully open content (the AI can freely quote) and one for restricted (the AI can use for inspiration but should rephrase and cite). This can be enforced at query time in the retrieval system.

* **Updates and Expiration:** Some data (like FDA safety notices) might be updated or superseded. The pipeline should be able to update existing entries (for example, if a clinical trial status changes from “recruiting” to “completed with results”). Implement logic to **upsert** rather than only append. Also, consider *retiring* data that is no longer relevant (if needed, e.g., outdated guidelines – though usually better to mark as superseded rather than delete, for historical reference).

* **Dagster Assets for Downstream Use:** The pipeline not only ingests data but can trigger downstream tasks. For instance, once data is in the library, another Dagster job could periodically train or fine-tune an embedding model or language model on the accumulated corpus. Or update a dashboard of stats. This ensures **end-to-end automation** from data ingestion to model update.

### **Source Prioritization Rationale**

Prioritization is important given finite engineering resources and data volume. We rank sources by:

* **Ease of Access & Scraping:** Sources with robust APIs and structured data (PubMed, openFDA, ClinicalTrials.gov) come first – they are low-hanging fruit. Conversely, sources needing heavy scraping or manual steps (videos, textbooks) are later.

* **Licensing Clarity:** Public domain or CC0 (government data, openFDA) and CC licensed (open journals) are high priority because we can use them freely. Ambiguously licensed but public (society reports) are moderate priority with careful use. Strictly copyrighted (commercial journals) are lowest priority unless critical, due to the overhead of transformation needed.

* **Relevance to Clinical Decision-Making:** Content that directly informs patient care (e.g. FDA safety data, clinical studies, guidelines) is top priority. General knowledge or nice-to-have (like historical data or social media content) is lower. The ingestion schedule can reflect this: e.g., new FDA alerts might be ingested immediately (same day), whereas Wikipedia updates can be checked monthly.

* **Format Compatibility:** Textual data in HTML/JSON is easiest to integrate; PDF scanning or audio/video transcription requires more resources. We plan to implement all, but initially focus on text. Over time, as the pipeline stabilizes, incorporate the more complex formats (having tested the approach on a smaller scale first).

Concretely, an initial rollout might ingest open texts (journals, PubMed, FDA) in Phase 1, then add multimedia (video/podcast with summarization pipelines) in Phase 2, and finally incorporate any remaining niche sources (textbooks via summaries) in Phase 3\. Dagster’s orchestrator will allow these to run concurrently once fully deployed, ensuring the Global Library continuously expands and stays updated.

## **Data Ingestion Pipeline Summary Table**

Below is a **summary table** of each data source category, including licensing, ingestion method, data format, and how A360’s AI will use the data downstream:

| Data Source | License/Permissions | Ingestion Method | Data Format | Downstream Usage |
| ----- | ----- | ----- | ----- | ----- |
| **PubMed & PubMed Central** (biomedical literature) | PubMed abstracts – copyrighted (fair use for brief use); PMC Open Access articles – Creative Commons licenses (e.g. CC BY). | NCBI E-utilities API for abstracts; PMC OAI-PMH and FTP for full texts. Automated queries for new papers. | XML/JSON for metadata; PDF/HTML for full text. | Fine-tune language model on medical text; semantic search embeddings for Q\&A; cite articles as evidence in care plans and recommendations. |
| **Open-Access Journals** (PRS Global Open, JPRAS Open, etc.) | Creative Commons licenses (mix of CC BY, CC BY-NC-ND) – free to reuse with attribution. Content is openly accessible online. | Scrape publisher sites or use DOAJ/PMC feeds. Download PDF or HTML of articles. Parse into text. | PDF, HTML, or XML articles. | Train models on domain-specific content (improves answer accuracy on aesthetic topics); provide reference material in Global Library; use in retrieval-augmented generation with direct quoting (with citation). |
| **FDA Data (openFDA: devices, drugs, etc.)** | Public domain (CC0) – no restrictions for data. Open use intended by FDA. | REST API calls (open.fda.gov) for JSON data; scheduled pulls for new adverse events, device listings, etc. | JSON structured data (also CSV for bulk). | Feed a database of device/drug safety info; support AI in answering safety/regulatory questions; include stats (e.g., recall info, adverse event rates) in care plan generation. |
| **ClinicalTrials.gov** (trial registry) | Publicly provided data; considered public domain (government-run). No explicit license, but reuse of facts is allowed. | API queries or bulk download of trial records (XML/JSON). Filter by keywords (aesthetic). Update status periodically. | XML/JSON records (structured fields). | Inform evidence-based guidance (e.g., notify if a treatment is experimental or trial-backed); allow AI to mention ongoing research and results data; enhance model’s understanding of outcomes. |
| **Society Reports & Guidelines** (ASPS/ISAPS reports, consensus guidelines) | Copyrighted by organizations (all rights reserved) but published openly. Fair use of facts and brief excerpts with credit. | Download PDFs from official sites; parse text and tables. Some manual curation for context. | PDF documents (text, tables, charts). | Provide trend data and statistics in AI responses (with citation); incorporate recommended best practices from guidelines into decision support; use facts (procedure counts, etc.) in analytics and planning tools. |
| **Medical Device Manuals** (manufacturer PDFs, FDA summaries) | Copyrighted by manufacturers. No open license. Allowed use under fair use: extract facts, summarize instructions (transformative use). | Manual download or scraping of PDF manuals; parse key sections. Possibly use FDA device summary (public domain) for core info. | PDF text; some HTML from FDA databases. | Internal reference for device usage parameters; AI can check contraindications or settings when formulating treatment plans (without quoting manual text verbatim); supports safety checks in recommendations. |
| **Creative Commons Educational Content** (Wikipedia, open textbooks, images) | CC BY-SA (Wikipedia) – free with attribution & share-alike; other OER may be CC BY or BY-NC. Wikimedia images vary (many CC BY/PD). | Wikipedia API to fetch article content; scrape known OER sites or use provided downloads; download images with metadata. | HTML/Wikitext for articles; PDF/EPUB for textbooks; JPG/PNG for images. | General knowledge augmentation (helps AI explain concepts or procedures in simple terms); patient education materials (leveraging layperson-friendly text); use images in Global Library for illustration or future model training in vision. |
| **YouTube Videos (surgery demos, lectures)** | Standard YouTube license (copyrighted). **Usage via fair use**: must transform (summaries, short snippets). API allows access to metadata; downloading content otherwise restricted. | YouTube Data API for titles/descriptions; use YouTube captions if available or run speech-to-text on video audio. Then summarize key points. (Human review recommended.) | Video/audio file (MP4), transcribed text. | Add practical surgical “tips” and procedural insights to knowledge base; AI can answer “how-to” questions with guidance gleaned from experts (citing the video source); supports training conversational understanding of procedural discussions. |
| **Medical Podcasts** (expert interviews, discussions) | Copyrighted audio content. Fair use via transformation (transcript summaries, quotes). Typically no transcript provided by creators, so A360-generated transcripts need careful use. | Fetch podcast RSS feeds; download audio; transcribe with ASR. Summarize discussions or extract Q\&A pairs. Possibly involve a human editor for accuracy. | Audio (MP3); transcribed text. | Infuse expert opinions and clinical pearls into AI’s knowledge (e.g., “expert consensus” type answers); use conversational tone data to improve AI’s interaction style; cite podcast episode in answers for credibility. |
| **Commercial Journals (closed access)** and **Textbooks** | Strict copyright (no reuse of text). **Strategy**: manual or AI-assisted summaries, fact extraction, and citation. No direct text ingestion without permission. | Manual selection of key articles/chapters; experts or summarization models create digests of each source. Store only the new summaries and data points. Track original source reference. | Original source in PDF/print (not stored); Derived summary text and structured data. | Fill knowledge gaps on specialized or proprietary topics (ensures AI isn’t blind to important info behind paywalls); model training on summaries (which are in A360’s words) to incorporate high-level knowledge; when answering, use these as cited evidence without exposing original text. |
| **Internal/Partner Data** (if any, e.g., patient outcomes, proprietary datasets) | Protected by privacy laws or NDA. Not for public library inclusion. Can be used for internal model training with compliance (de-identification, aggregation). | Secure pipelines separate from public data (not Dagster if it involves PHI unless on secure infrastructure). Possibly ingestion via database connections or CSV import with encryption. | Structured data (CSV, SQL tables); possibly images. | Improve model’s predictive capabilities (e.g., outcome prediction) and personalization of advice. Not directly exposed to users, but informs AI’s internal logic. (Outside scope of public Global Library content.) |

**Table Legend:** Open-use sources are in the upper section of the table, while restricted sources (where special handling is needed) are lower down. License types highlight the allowed usage (CC \= Creative Commons, PD \= public domain). Ingestion methods note whether we use APIs or scraping and any special processing. Downstream usage shows how each source will concretely benefit A360’s AI-driven products (from training enhancements to real-time information retrieval).

---

**Conclusion:** This technical research compendium serves as an implementation reference for building A360’s Global Library. By leveraging a wide array of data sources — from openly licensed medical literature and government datasets to carefully curated insights from multimedia and commercial content — A360 can develop a robust, up-to-date knowledge base for aesthetic medicine and plastic surgery. The recommended Dagster pipeline architecture will ensure the data is ingested efficiently, kept fresh, and used in compliance with licenses and fair use principles. By prioritizing high-relevance and legally clear sources while applying transformation strategies to restricted materials, A360’s AI models can be fine-tuned and augmented with domain-specific expertise. The result will empower clinicians and stakeholders with accurate decision support, evidence-backed recommendations, and comprehensive educational resources via the Global Library, all underpinned by a solid data engineering framework.

